GLS基因功能缺失突变致谷氨酰胺酶缺乏与新生儿癫痫性脑病
该研究对2个家系4名表现为难治性新生儿癫痫、呼吸衰竭、脑结构异常并早期死亡的患儿行外显子测序,鉴定出GLS基因的纯合或复合杂合功能缺失突变,血谷氨酰胺升高,提示谷氨酰胺酶缺乏是致死性新生儿脑病的常染色体隐性病因。
要点
- 对不明原因致死性新生儿癫痫性脑病应考虑GLS相关谷氨酰胺酶缺乏。
- GLS双等位功能缺失突变可致谷氨酰胺升高、谷氨酸减少。
- 该病呈常染色体隐性,表现为难治性癫痫、呼吸衰竭与脑结构异常。
核心结论
- GLS功能缺失突变导致谷氨酰胺酶缺乏,引发致死性早期新生儿脑病。
研究设计与样本
- 对2个家系共4名致死性新生儿癫痫性脑病患儿行外显子测序及候选变异生物信息学评估。
- 通过干血斑亲水相互作用液相色谱串联质谱检测代谢物以确立变异致病性。
主要发现
- 4名患儿均于出生后40天内死亡,表现为难治性早期新生儿癫痫持续状态、爆发抑制、呼吸功能不全、脑回结构简化、弥漫性脑体积丢失及脑水肿。
- 家系1检出GLS纯合移码变异p.(Asp232Glufs*2),家系2检出GLS复合杂合变异p.(Gln81*)与p.(Arg272Lys)。
- 3个变异均可能导致功能缺失,患儿谷氨酰胺升高(可得的z分数为3.2和11.7)。
临床怎么用
- 对难治性新生儿癫痫伴呼吸衰竭及脑结构异常者,可考虑GLS基因检测与血谷氨酰胺评估。
局限性
- 仅基于2个家系4名患儿的遗传与代谢发现,未报告功能实验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The identification and understanding of the monogenic causes of neurodevelopmental disorders are of high importance for personalized treatment and genetic counseling. OBJECTIVE: To identify and characterize novel genes for a specific neurodevelopmental disorder characterized by refractory seizures, respiratory failure, brain abnormalities, and death in the neonatal period; describe the outcome of glutaminase deficiency in humans; and understand the underlying pathological mechanisms. DESIGN, SETTING, AND PARTICIPANTS: We performed exome sequencing of cases of neurodevelopmental disorders without a clear genetic diagnosis, followed by genetic and bioinformatic evaluation of candidate variants and genes. Establishing pathogenicity of the variants was achieved by measuring metabolites in dried blood spots by a hydrophilic interaction liquid chromatography method coupled with tandem mass spectrometry. The participants are 2 families with a total of 4 children who each had lethal, therapy-refractory early neonatal seizures with status epilepticus and suppression bursts, respiratory insufficiency, simplified gyral structures, diffuse volume loss of the brain, and cerebral edema. Data analysis occurred from October 2017 to June 2018. MAIN OUTCOMES AND MEASURES: Early neonatal epileptic encephalopathy with glutaminase deficiency and lethal outcome. RESULTS: A total of 4 infants from 2 unrelated families, each of whom died less than 40 days after birth, were included. We identified a homozygous frameshift variant p.(Asp232Glufs*2) in GLS in the first family, as well as compound heterozygous variants p.(Gln81*) and p.(Arg272Lys) in GLS in the second family. The GLS gene encodes glutaminase (Enzyme Commission 3.5.1.2), which plays a major role in the conversion of glutamine into glutamate, the main excitatory neurotransmitter of the central nervous system. All 3 variants probably lead to a loss of function and thus glutaminase deficiency. Indeed, glutamine was increased in affected children (available z scores, 3.2 and 11.7). We theorize that the potential reduction of glutamate and the excess of glutamine were a probable cause of the described physiological and structural abnormalities of the central nervous system. CONCLUSIONS AND RELEVANCE: We identified a novel autosomal recessive neurometabolic disorder of loss of function of glutaminase that leads to lethal early neonatal encephalopathy. This inborn error of metabolism underlines the importance of GLS for appropriate glutamine homeostasis and respiratory regulation, signal transduction, and survival.
引用
- Rumping L, Büttner B, Maier O, et al. Identification of a Loss-of-Function Mutation in the Context of Glutaminase Deficiency and Neonatal Epileptic Encephalopathy. JAMA Neurol. 2019. PMID: 30575854. doi:10.1001/jamaneurol.2018.2941
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。